BERLIN (Reuters) – Swiss pharmaceutical group Novartis (SIX:NOVN) is winding up the German biotech company Morphosys (ETR:MORG), which it acquired at the beginning of the year, German news outlet WirtschaftsWoche reported on Thursday, saying 330 jobs would be affected.
“In November 2024, we made the decision to close the Morphosys sites in Germany and the U.S. by the end of 2025 and to integrate all portfolio activities into Novartis,” WiWo cited Novartis as saying.
Novartis did not immediately respond to an emailed request for comment from Reuters.
($1 = 0.9610 euros)
